Galectin Therapeutics Inc. (GALT)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.2M) | (3.4M) | (4.1M) | (4.0M) |
| Net Income | (8.2M) | (5.5M) | (5.0M) | (9.1M) |
| Diluted EPS | $-0.13 | N/A | $-0.08 | $-0.14 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (38.4M) | (38.1M) | (42.4M) | (20.1M) |
| Net Income | (38.8M) | (41.1M) | (47.0M) | (30.8M) |
| Diluted EPS | $-0.65 | $-0.74 | $-0.76 | $-0.48 |